Compare Stocks: HOLX, BSX, BDX, and EW

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$183.21 +3.0%	$173.06	$127.59 ▼ $193.07	$49.00B	0.21	1.56 million shs	1.63 million shs
BSX Boston Scientific	$44.85 +4.3%	$47.00	$42.20 ▼ $105.65	$62.29B	0.57	19.62 million shs	20.39 million shs
EW Edwards Lifesciences	$85.58 +1.4%	$88.97	$72.30 ▼ $96.29	$48.58B	0.85	2.65 million shs	2.99 million shs
HOLX Hologic	$76.01	$75.56	$51.90 ▼ $76.07	$16.97B	0.7	3.29 million shs	102.03 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	+3.02%	-0.85%	+0.03%	+26.11%	-2.14%
BSX Boston Scientific	+4.30%	-6.28%	-13.37%	-4.42%	-56.34%
EW Edwards Lifesciences	+1.22%	-4.92%	-6.49%	-3.37%	+10.42%
HOLX Hologic	0.00%	0.00%	0.00%	0.00%	+17.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDX Becton, Dickinson and Company	$183.21 +3.0%	$173.06	$127.59 ▼ $193.07	$49.00B	0.21	1.56 million shs	1.63 million shs
BSX Boston Scientific	$44.85 +4.3%	$47.00	$42.20 ▼ $105.65	$62.29B	0.57	19.62 million shs	20.39 million shs
EW Edwards Lifesciences	$85.58 +1.4%	$88.97	$72.30 ▼ $96.29	$48.58B	0.85	2.65 million shs	2.99 million shs
HOLX Hologic	$76.01	$75.56	$51.90 ▼ $76.07	$16.97B	0.7	3.29 million shs	102.03 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDX Becton, Dickinson and Company	+3.02%	-0.85%	+0.03%	+26.11%	-2.14%
BSX Boston Scientific	+4.30%	-6.28%	-13.37%	-4.42%	-56.34%
EW Edwards Lifesciences	+1.22%	-4.92%	-6.49%	-3.37%	+10.42%
HOLX Hologic	0.00%	0.00%	0.00%	0.00%	+17.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDX Becton, Dickinson and Company	2.41	Hold	$187.67	2.43% Upside
BSX Boston Scientific	2.71	Moderate Buy	$71.46	59.35% Upside
EW Edwards Lifesciences	2.74	Moderate Buy	$100.27	17.18% Upside
HOLX Hologic	2.00	Hold	$79.13	4.10% Upside

Current Analyst Ratings Breakdown

Latest HOLX, BSX, BDX, and EW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	EW Edwards Lifesciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$110.00
9/9/2026	BSX Boston Scientific	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$60.00 ➝ $56.00
8/31/2026	BDX Becton, Dickinson and Company	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$185.00 ➝ $200.00
8/25/2026	BSX Boston Scientific	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$56.00
8/13/2026	BDX Becton, Dickinson and Company	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/13/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$180.00 ➝ $190.00
8/7/2026	BDX Becton, Dickinson and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
8/7/2026	BDX Becton, Dickinson and Company	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$195.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$175.00 ➝ $180.00
8/7/2026	BDX Becton, Dickinson and Company	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Hold
8/7/2026	BDX Becton, Dickinson and Company	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$198.00 ➝ $204.00

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDX Becton, Dickinson and Company	$21.84B	2.31	$23.76 per share	7.71	$88.58 per share	2.07
BSX Boston Scientific	$20.07B	3.24	$4.21 per share	10.65	$16.49 per share	2.72
EW Edwards Lifesciences	$6.07B	8.12	$2.89 per share	29.59	$17.81 per share	4.80
HOLX Hologic	$4.10B	4.14	$5.74 per share	13.25	$22.69 per share	3.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDX Becton, Dickinson and Company	$1.68B	$3.32	55.18	13.84	12.53	4.52%	14.79%	6.93%	11/5/2026 (Estimated)
BSX Boston Scientific	$2.90B	$2.47	18.16	13.11	1.00	17.50%	19.28%	10.89%	10/28/2026 (Estimated)
EW Edwards Lifesciences	$1.07B	$1.74	49.18	25.24	2.21	15.43%	15.68%	12.05%	10/29/2026 (Estimated)
HOLX Hologic	$565.70M	$2.40	31.67	16.45	2.24	13.18%	19.58%	10.88%	N/A

Latest HOLX, BSX, BDX, and EW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q3 2026	BDX Becton, Dickinson and Company	$3.14	$3.23	+$0.09	$1.37	$4.89 billion	$4.98 billion
7/29/2026	Q2 2026	BSX Boston Scientific	$0.83	$0.86	+$0.03	$0.61	$5.38 billion	$5.44 billion
7/23/2026	Q2 2026	EW Edwards Lifesciences	$0.7430	$0.78	+$0.0370	$0.42	$1.70 billion	$1.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDX Becton, Dickinson and Company	$4.20	2.29%	+5.65%	126.51%	53 Years
BSX Boston Scientific	N/A	N/A	N/A	N/A	N/A
EW Edwards Lifesciences	N/A	N/A	N/A	N/A	N/A
HOLX Hologic	N/A	N/A	N/A	N/A	N/A

Latest HOLX, BSX, BDX, and EW Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	BDX Becton, Dickinson and Company	quarterly	$1.05	2.33%	9/9/2026	9/9/2026	9/30/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDX Becton, Dickinson and Company	0.55	0.87	0.51
BSX Boston Scientific	0.43	1.24	0.74
EW Edwards Lifesciences	0.06	4.52	3.77
HOLX Hologic	0.48	4.04	3.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDX Becton, Dickinson and Company	86.97%
BSX Boston Scientific	89.07%
EW Edwards Lifesciences	79.46%
HOLX Hologic	94.73%

Insider Ownership

Company	Insider Ownership
BDX Becton, Dickinson and Company	0.40%
BSX Boston Scientific	0.34%
EW Edwards Lifesciences	0.31%
HOLX Hologic	1.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDX Becton, Dickinson and Company	72,000	275.54 million	274.44 million	Optionable
BSX Boston Scientific	59,000	1.45 billion	1.44 billion	Optionable
EW Edwards Lifesciences	16,000	575.80 million	574.02 million	Optionable
HOLX Hologic	7,070	223.24 million	219.05 million	Optionable

HOLX, BSX, BDX, and EW Headlines

Recent News About These Companies

Hologic stock heads into the open after a 2.1 percent drop

September 9, 2026 | ad-hoc-news.deA

CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening

July 14, 2026 | finance.yahoo.com

Blackstone and TPG seek more than $4bn for Hologic unit to unlock cash

July 10, 2026 | ft.com

Blackstone, TPG seek over $4 billion for Hologic's surgical unit, FT says

July 9, 2026 | reuters.com

FDA updates Hologic BioZorb recall, citing 252 injuries

July 1, 2026 | yahoo.com

Hologic Inc.

June 17, 2026 | wsj.com

Court Determines Siemens Infringed on Hologic Mammography Patent

June 17, 2026 | mddionline.comM

Hologic’s New Sustainability Report Marks 40 Years of Impact

June 17, 2026 | finance.yahoo.com

Needles used to detect breast cancer in shortage from recall

June 17, 2026 | fortune.com

Hologic's New Sustainability Report Marks 40 Years of Impact

June 17, 2026 | businesswire.com

Hologic earns patent battle victory over Siemens Heatlhineers, mandates mammography system recall

June 17, 2026 | massdevice.com

Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

May 28, 2026 | timesargus.comT

New Hampshire Justices Dissect Hologic’s Business Tax Method

May 12, 2026 | news.bloomberglaw.comN

OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic's Aptima HPV Assay

May 11, 2026 | finance.yahoo.com

New Evidence Backs Hologic's AI-Powered Mammography Technology for Detecting Challenging Cancers

April 20, 2026 | businesswire.com

Hologic Goes Private In $18 Billion Blackstone, TPG Acquisition

April 8, 2026 | benzinga.com

A look back at medical devices & supplies - imaging, diagnostics stocks’ Q4 earnings: Hologic (NASDAQ:HOLX) vs the rest of the pack

April 8, 2026 | msn.com

Hologic Stock at 52-Week High in 2026: Buy or Sell Ahead of $18.3 Billion Blackstone Takeover Closure?

April 8, 2026 | ibtimes.comI

Hologic (HOLX) Goes Private: Blackstone and TPG Close $17 Billion Acquisition

April 7, 2026 | blockonomi.com

Hologic Taken Private in Blackstone-TPG Acquisition, Leadership Shift

April 7, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HOLX, BSX, BDX, and EW Company Descriptions

Becton, Dickinson and Company NYSE:BDX

$183.21 +5.36 (+3.02%)

Closing price 09/14/2026 03:59 PM Eastern

Extended Trading

$182.98 -0.24 (-0.13%)

As of 04:20 AM Eastern

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Boston Scientific NYSE:BSX

$44.85 +1.87 (+4.34%)

Closing price 09/14/2026 03:59 PM Eastern

Extended Trading

$45.00 +0.16 (+0.35%)

As of 04:52 AM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Edwards Lifesciences NYSE:EW

$85.58 +1.21 (+1.43%)

Closing price 09/14/2026 03:59 PM Eastern

Extended Trading

$85.29 -0.28 (-0.33%)

As of 04:42 AM Eastern

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Hologic NASDAQ:HOLX

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOLX, BSX, BDX, and EW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOLX, BSX, BDX, and EW Earnings

Compare Dividends

Latest HOLX, BSX, BDX, and EW Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOLX, BSX, BDX, and EW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HOLX, BSX, BDX, and EW Company Descriptions

Becton, Dickinson and Company NYSE:BDX

Boston Scientific NYSE:BSX

Edwards Lifesciences NYSE:EW

Hologic NASDAQ:HOLX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools